Evidence map›Paper›PMID 21135504›Full record

ArticleThe Journal of clinical investigation2011

The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer.

Norma E Ramirez, Zhonghua Zhang, Aasakiran Madamanchi, Kelli L Boyd, Lynda D O'Rear, Abudi Nashabi, Zhengzi Li, William D Dupont, Andries Zijlstra, Mary M Zutter

Open access · greenAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 1 synthesis or guideline pooled it, 207 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. From Plastics to Prognosis:Diagnostics (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Mechanisms of angiogenesis in tumour.Frontiers in oncology · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Norma E RamirezDepartment of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2561, USA.
Zhonghua Zhang
Aasakiran Madamanchi
Kelli L Boyd
Lynda D O'Rear
Abudi Nashabi
Zhengzi Li
William D Dupont
Andries Zijlstra
Mary M Zutter
Vanderbilt University Medical Center · US

Funding

TISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7M
TrainingU54CA163072 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Karen Marie Winkfield · 2011 to 2026
$20.1M
The alpha2beta1 Integrin: Innate Immunity to Pathogens & TumorsR01CA098027 · NCI · WASHINGTON UNIVERSITY · PI ZUTTER, MARY M. · 2003 to 2013
$3.3M
ALTERED ALPHA-2 INTEGRIN EXPRESSION IN BREAST CANCERR01CA070275 · NCI · WASHINGTON UNIVERSITY · PI ZUTTER, MARY M. · 1996 to 2005
$1.8M
Tetraspanin-mediated regulation of tumor cell migration and metastasisR01CA143081 · NCI · VANDERBILT UNIVERSITY · PI ZIJLSTRA, ANDRIES · 2010 to 2014
$1.5M
Unexpected Roles for the alpha2beta1 IntegrinR01CA115984 · NCI · VANDERBILT UNIVERSITY · PI ZUTTER, MARY M. · 2005 to 2009
$1.5M
The molecular mechanisms of migration of which lead to tumor cell intravasation.K01CA120711 · NCI · VANDERBILT UNIVERSITY · PI ZIJLSTRA, ANDRIES · 2007 to 2011
$719k
NCI NIH HHS CA098027NCI NIH HHS CA098131-07NCI NIH HHS CA115984NCI NIH HHS CA70275NCI NIH HHS K01 CA120711NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA070275NCI NIH HHS R01 CA098027NCI NIH HHS R01 CA115984NCI NIH HHS R01 CA143081NCI NIH HHS U54 CA163072
6 · The paper itself

Abstract

Integrins regulate cell-cell and cell-matrix adhesion and thereby play critical roles in tumor progression and metastasis. Although work in preclinical models suggests that β1 integrins may stimulate metastasis of a number of cancers, expression of the β1 subunit alone has not been shown to be a useful prognostic indicator in human cancer patients. Here we have demonstrated that the α2β1 integrin suppresses metastasis in a clinically relevant spontaneous mouse model of breast cancer. These data are consistent with previous studies indicating high expression of α2β1 integrin in normal breast epithelium and loss of α2β1 in poorly differentiated breast cancer. They are also consistent with our systematic analysis of microarray databases of human breast and prostate cancer, which revealed that decreased expression of the gene encoding α2 integrin, but not genes encoding α1, α3, or β1 integrin, was predictive of metastatic dissemination and decreased survival. The predictive value of α2 expression persisted within both good-risk and poor-risk cohorts defined by estrogen receptor and lymph node status. Thus, the α2β1 integrin functionally inhibits breast tumor metastasis, and α2 expression may serve as an important biomarker of metastatic potential and patient survival.

Indexed as

AnimalsBase SequenceBiomarkers, TumorBreast NeoplasmsDNA PrimersFemaleGenes, erbB-2HumansIntegrin alpha2beta1In Vitro TechniquesKaplan-Meier EstimateMaleMammary Neoplasms, ExperimentalMiceMice, KnockoutMice, TransgenicBiomarkers, TumorDNA PrimersIntegrin alpha2beta1Tumor Suppressor Proteins

Identifiers

PMID21135504
PMCPMC3007139
OpenAlexW2118487323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.